AbbVie CEO and Chairman Rick Gonzalez gave a good update on Japan for hepatitis C treatment Viekira which entered a market in December already served by Harvoni from Gilead Sciences and Bristol-Myers Squibb product Daklinza.
Over the past couple of quarters, AbbVie investors have bristled at the sight of top-seller Humira missing expectations outside the U.S. In Q4, though, the world's best seller rebounded outside its home country, topping predictions to help sales and profits stay generally in line despite a rough U.S. quarter for hep C drug Viekira Pak.
AbbVie and Roche's venetoclax has received yet another accelerated review from the FDA--this time in patients with the most common type of acute leukemia.
Abbott has partnered with Chicago, IL-based Matter, a healthcare technology incubator, in its latest bid to access innovation. The diversified conglomerate, which markets nutrition, diagnostics, established pharmaceutical and medical device products, is under pressure to improve revenue growth and profitability in the wake of its 2013 split from the biopharma R&D-oriented AbbVie.
Amgen's take on AbbVie's top-selling inflammation treatment is in line for FDA approval this year, but a patent fight between the two companies could keep it off the market into the next decade.
Galapagos has kicked off a Phase I trial of its AbbVie-partnered cystic fibrosis (CF) drug, GLPG2222. The start of the trial marks another milestone in the rolling advance of Galapagos' multipronged attack on CF, which is set to be bolstered later this year by the emergence of more next-generation correctors.
AbbVie and Roche's cancer drug venetoclax, awaiting FDA approval, picked up another breakthrough therapy nod from the agency for its potential as part of a combination treatment for leukemia.
Amgen has hit a potential snag in its quest to bring a biosimilar of AbbVie cash cow Humira to market. Thursday, the U.S. Patent and Trademark Office declined to review a pair of formulation patents on the arthritis drug, determining that "based on the petition and the accompanying evidence … Amgen has not shown a reasonable likelihood of prevailing on any of its challenges," Reuters reports.
Amgen, at work on a biosimilar of AbbVie's best-selling treatment, got an unfavorable decision from U.S. regulators that could delay the launch of its take on Humira.
AbbVie and Roche scored priority review for their new leukemia therapy venetoclax, putting the companies in line for a launch within 6 months. With analysts predicting 2020 sales of $2 billion--and both companies expecting biosimilar competition by 2018--the med could be a welcome addition to their lineups.